Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI)

International Journal of Cardiology

Volumn 177, Issue 3, 2014, Pages 912-917

  Baldenhofer, Gerd ^a   Zhang, Kun ^a   Spethmann, Sebastian ^a   Laule, Michael ^a   Eilers, Björn ^a   Leonhardt, Franziska ^a   Sanad, Wasiem ^a   Dreger, Henryk ^a   Sander, Michael ^a   Grubitzsch, Herko ^a   Baumann, Gert ^a   Stangl, Karl ^a   Stangl, Verena ^a   Knebel, Fabian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aortic valve stenosis; Galectin 3; Transcatheter aortic valve implantation

Indexed keywords

GALECTIN 3;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84920143254     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.10.010     Document Type: Article

References (32)

1. F. Schwarz, P. Baumann, J. Manthey, M. Hoffmann, G. Schuler, and H.C. Mehmel The effect of aortic valve replacement on survival Circulation 66 1982 1105 1110
2. R.L. Osnabrugge, D. Mylotte, S.J. Head, N.M. Van Mieghem, V.T. Nkomo, and C.M. LeReun Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study J Am Coll Cardiol 62 2013 1002 1012
3. R.R. Makkar, G.P. Fontana, H. Jilaihawi, S. Kapadia, A.D. Pichard, and P.S. Douglas Transcatheter aortic-valve replacement for inoperable severe aortic stenosis N Engl J Med 366 2012 1696 1704
4. C.R. Smith, M.B. Leon, M.J. Mack, D.C. Miller, J.W. Moses, and L.G. Svensson Transcatheter versus surgical aortic-valve replacement in high-risk patients N Engl J Med 364 2011 2187 2198
5. Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio-Thoracic S, A. Vahanian, O. Alfieri, F. Andreotti, and M.J. Antunes Guidelines on the management of valvular heart disease (version 2012) Eur Heart J 33 2012 2451 2496
6. S.A. Nashef, F. Roques, P. Michel, E. Gauducheau, S. Lemeshow, and R. Salamon European system for cardiac operative risk evaluation (EuroSCORE) Eur J Cardiothorac Surg 16 1999 9 13
7. J. Basraon, Y.S. Chandrashekhar, R. John, A. Agnihotri, R. Kelly, and H. Ward Comparison of risk scores to estimate perioperative mortality in aortic valve replacement surgery Ann Thorac Surg 92 2011 535 540
8. F. Barili, D. Pacini, A. Capo, E. Ardemagni, G. Pellicciari, and M. Zanobini Reliability of new scores in predicting perioperative mortality after isolated aortic valve surgery: a comparison with the society of thoracic surgeons score and logistic EuroSCORE Ann Thorac Surg 95 2013 1539 1544
9. J.M. Sinning, A. Ghanem, H. Steinhauser, V. Adenauer, C. Hammerstingl, and G. Nickenig Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation JACC Cardiovasc Interv 3 2010 1141 1149
10. A.W. Schoenenberger, S. Stortecky, S. Neumann, A. Moser, P. Juni, and T. Carrel Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI) Eur Heart J 34 2013 684 692
11. J. Rodes-Cabau, J.G. Webb, A. Cheung, J. Ye, E. Dumont, and M. Osten Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience J Am Coll Cardiol 60 2012 1864 1875
12. M. Thomas, G. Schymik, T. Walther, D. Himbert, T. Lefevre, and H. Treede One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve Circulation 124 2011 425 433
13. W.H. Tang, K. Shrestha, Z. Shao, A.G. Borowski, R.W. Troughton, and J.D. Thomas Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival Am J Cardiol 108 2011 385 390
14. R.A. De Boer, A.A. Voors, P. Muntendam, W.H. van Gilst, and D.J. van Veldhuisen Galectin-3: a novel mediator of heart failure development and progression Eur J Heart Fail 11 2009 811 817
15. R.A. De Boer, D.J. Lok, T. Jaarsma, P. van der Meer, A.A. Voors, and H.L. Hillege Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
16. T. Ueland, P. Aukrust, K. Broch, S. Aakhus, R. Skardal, and P. Muntendam Galectin-3 in heart failure: high levels are associated with all-cause mortality Int J Cardiol 150 2011 361 364
17. R.A. De Boer, D.J. van Veldhuisen, R.T. Gansevoort, A.C. Muller Kobold, W.H. van Gilst, and H.L. Hillege The fibrosis marker galectin-3 and outcome in the general population J Intern Med 272 2012 55 64
18. J.E. Ho, C. Liu, A. Lyass, P. Courchesne, M.J. Pencina, and R.S. Vasan Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 2012 1249 1256
19. R.A. De Boer, F. Edelmann, A. Cohen-Solal, M.A. Mamas, A. Maisel, and B. Pieske Galectin-3 in heart failure with preserved ejection fraction Eur J Heart Fail 15 2013 1095 1101
20. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, and P.A. Pellikka Recommendations for chamber quantification Eur J Echocardiogr 7 2006 79 108
21. H. Baumgartner, J. Hung, J. Bermejo, J.B. Chambers, A. Evangelista, and B.P. Griffin Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice J Am Soc Echocardiogr 22 2009 1 23 [quiz 101-2]
22. V. Stangl, G. Baldenhofer, F. Knebel, K. Zhang, W. Sanad, and S. Spethmann Impact of gender on three-month outcome and left ventricular remodeling after transfemoral transcatheter aortic valve implantation Am J Cardiol 110 2012 884 890
23. A.P. Kappetein, S.J. Head, P. Genereux, N. Piazza, N.M. van Mieghem, and E.H. Blackstone Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document J Am Coll Cardiol 60 2012 1438 1454
24. P.A. McCullough, A. Olobatoke, and T.E. Vanhecke Galectin-3: a novel blood test for the evaluation and management of patients with heart failure Rev Cardiovasc Med 12 2011 200 210
25. U.C. Sharma, S. Pokharel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, and B. Schroen Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
26. L. Calvier, M. Miana, P. Reboul, V. Cachofeiro, E. Martinez-Martinez, and R.A. De Boer Galectin-3 mediates aldosterone-induced vascular fibrosis Arterioscler Thromb Vasc Biol 33 2013 67 75
27. T. Ahmad, and G.M. Felker Galectin-3 in heart failure: more answers or more questions? J Am Heart Assoc 1 2012 e004374
28. T.H. Tsai, P.H. Sung, L.T. Chang, C.K. Sun, K.H. Yeh, and S.Y. Chung Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention J Atheroscler Thromb 19 2012 1073 1082
29. A.R. van der Velde, L. Gullestad, T. Ueland, P. Aukrust, Y. Guo, and A. Adourian Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH Circ Heart Fail 6 2013 219 226
30. C.F. Azevedo, M. Nigri, M.L. Higuchi, P.M. Pomerantzeff, G.S. Spina, and R.O. Sampaio Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease J Am Coll Cardiol 56 2010 278 287
31. G.M. Felker, M. Fiuzat, L.K. Shaw, R. Clare, D.J. Whellan, and L. Bettari Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Circ Heart Fail 5 2012 72 78
32. D.J. Lok, P. Van Der Meer, P.W. De la Porte, E. Lipsic, J. Van Wijngaarden, and H.L. Hillege Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 2010 323 328